cancer

President Donald Trump‘s $3.3 trillion domestic agenda bill, passed by House Republicans on Thursday, includes a significant but little-noticed victory for pharmaceutical companies that will cost taxpayers nearly $5 billion over the next decade. What Happened: The legislation expands...

Cathie Wood, the founder, CEO, and CIO of Ark Invest, underscored the application of artificial intelligence in the healthcare sector by sharing new research by Mass General Brigham, citing the discovery of cancer survival using facial photograph analysis. What Happened: Wood reiterated her earlier...

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares are trading lower Friday following the release of updated interim data from its Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma. What To know: The...

Former U.S. President Joe Biden has been diagnosed with an aggressive form of prostate cancer that has metastasized to his bones, as reported by Reuters on Sunday. What Happened: The diagnosis was made on Friday after Biden, 82, experienced urinary symptoms. He and his family are currently...

Summit Therapeutics Inc. (NASDAQ:SMMT) on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 trial, HARMONi-2 or AK112-303. On Friday,...

Pliant Therapeutics, Inc. (NASDAQ:PLRX) released on Monday data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation trial of PLN-101095, in combination with Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab), in patients with immune...

H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ:CATX), a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer treatment. Analyst Robert Burns initiated a Buy rating and a price target of $10. The...

On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older)...

On Monday, Pfizer Inc (NYSE:PFE) revealed topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for...

Silexion Therapeutics Corp. (NASDAQ:SLXN) revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer. The additional preclinical data show that SIL-204 exhibits significant synergistic...

On Monday, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted a conditional marketing authorization to Amgen Inc’s (NASDAQ:AMGN) Imdylltra for extensive-stage small cell lung cancer with disease progression on or after at least two prior lines of therapy. Small cell...

Pyxis Oncology, Inc. (NASDAQ:PYXS) announced on Thursday, a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201. Pyxis Oncology’s second clinical program, PYX-106, is being deprioritized to allocate resources toward advancing the lead asset, PYX-201....

On Monday, the U.S. Food and Drug Administration issued a complete response letter (CRL) to Johnson & Johnson’s (NYSE:JNJ) Biologics License Application for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) in patients...

On Thursday, Tilray Medical, a division of medical marijuana giant Tilray Brands, Inc. (NASDAQ:TLRY), announced the final results of a new scientific study, “Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV).” Results showed that cannabis...

On Thursday, Aura Biosciences, Inc. (NASDAQ:AURA) revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC). To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility...